---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-23-000095"
form_type: "8-K"
ticker: "CFOR"
cik: "0001293818"
company_name: "CapForce Inc."
filed_at: "2023-01-18T23:59:59+00:00"
generated_at: "2026-06-20T13:48:49.657760+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OpGen reports preliminary 2022 revenue of $2.7M, within guidance; cash $7.4M; raises $7.5M in offering

## Summary
- Preliminary full-year 2022 revenue approximately $2.7M, within most recent guidance range.
- Cash position as of Dec 31, 2022: $7.4M; closed public offering on Jan 11, 2023 with gross proceeds $7.5M.
- Implemented 1-for-20 reverse stock split to regain Nasdaq minimum bid price compliance.
- UTI clinical trial achieved 96.4% sensitivity and 97.4% specificity; preparing FDA submission.
- Signed second Acuitas AMR Gene Panel customer contract and installed first two systems.

## SEC filing metadata
- accession: 0001079973-23-000095
- form_type: 8-K
- ticker: CFOR
- cik: 0001293818
- company_name: CapForce Inc.
- filed_at: 2023-01-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293818/000107997323000095/0001079973-23-000095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293818/000107997323000095/opgen_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-23-000095
- JSON: https://secwatch.observer/filing/0001079973-23-000095.json
- Plain text: https://secwatch.observer/filing/0001079973-23-000095.txt

## Key facts
- Earnings Releases
  CapForce Inc. reported year ended December 31, 2022 results: revenue approximately $2.7 million.
  - Period: year ended December 31, 2022
  - Revenue: approximately $2.7 million
  - Result: preliminary results
  source text: Preliminary revenue for full year 2022 was approximately $2.7 million, which falls within the most recent guidance range the Company had provided in its Q3 earnings call.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293818/000107997323000095/0001079973-23-000095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.